Abstract:Abstract Background: Downregulation or loss of TFF1 expression occurs in more than half of human gastric adenocarcinomas through gene deletions, mutation, and a loss of heterozygosity or hypermethylation. Our previous studies have shown that Tff1 knockout (KO) in mice induces gastric lesions from low- grade dysplasia (LGD), high- grade dysplasia (HGD) to adenocarcinoma. BRD2, a family member of BET proteins, promotes aberrant gene expression in a variety of malignant tumors. In this study, with the analysis of Tff1 KO mice and human gastric cancer tissue samples, we discovered that loss of Tff1 promotes gastric cancer proliferation and drug resistance through upregulating BRD2 expression level. Methods and Results: Integration Next Generation Sequencing data analysis in both Tff1 KO mice and human gastric cancer tissue samples demonstrated that miR-143-3p was significantly down-regulated in both mice and human gastric cancer samples (P<0.05). Our findings were further validated by RT-PCR in Tff1 KO mouse gastric legions (LGD and adenocarcinoma) and 3 different cohorts of human gastric cancer tissue samples from USA, Chile, and China. Using different gastric cancer cell models we further confirmed the decrease of miR-143-3p regulated by loss of TFF1. Next, we wanted to find out the downstream effector of miR-143-3p down-regulation. Western blot data showed that BRD2 protein level was regulated by miR-143-3p in 4 gastric cancer cell lines. BRD2 3'UTR luciferase reporter assay further confirmed that miR-143-3p decreased BRD2 protein expression through directly binding to its 3'UTR sites. These data suggested that, for the first time, BRD2 is a direct downstream target of miR-143-3p. At the meantime, the reconstitution of TFF1 in gastric cancer cells up-regulated miR-143-3p expression level, which in turn, decreased the protein expression levels of BRD2, MYC and BCL-2. Using western blot, we showed the synergistic effect of BRD2 inhibitor and CDDP chemotherapy in human gastric cancer cells. Data from 320 human gastric cancer patients demonstrated that high BRD2 expression level in gastric cancer tissues significantly decreased the overall patient survival rate (P<0.0001). Conclusion: This study unveils, for the first time, loss of TFF1 promotes BRD2 activation in gastric cancer through decreasing miR-143-3p. This axis presents novel therapeutic opportunities by using approaches that reconstitute miR-143-3p or utilizing the recently developed clinical trials in human gastric cancer. Citation Format: Zheng Chen, Zheng Li, Mohammed Soutto, Weizhi Wang, Shoumin Zhu, Alejandro Corvalan, Zekuan Xu, Wael El-Rifai. Loss of TFF1 promotes growth and chemotherapeutic resistance in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1259.

Biology of Human Tumors TMEFF 2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

Overexpression of TMEFF1 in Endometrial Carcinoma and the Mechanism Underlying its Promotion of Malignant Behavior in Cancer Cells

The Role of FERMT2 in the Tumor Microenvironment and Immunotherapy in Pan-Cancer Using Comprehensive Single-Cell and Bulk Sequencing

Bidirectional Regulation Between TMEFF2 and STAT3 May Contribute to Helicobacter Pylori-Associated Gastric Carcinogenesis.

TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease

TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway.

MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells.

Supplementary Table S2 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

Decreased Levels Of Active Smad2 Correlate With Poor Prognosis In Gastric Cancer

&Lt;p>tmeff2 Inhibits Pancreatic Cancer Cells Proliferation, Migration, and Invasion by Suppressing Phosphorylation of the MAPK Signaling Pathway</p>

Abstract 1259: Loss of TFF1 Promotes Growth and Chemotherapeutic Resistance in Gastric Cancer

Supplementary Table S1 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

MEF2D Functions as a Tumor Suppressor in Breast Cancer

Increased Expression of TMED2 is an Unfavorable Prognostic Factor in Patients with Breast Cancer

TMEM200A is a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Gastric Cancer.

Epigenetic and Tumor Microenvironment for Prognosis of Patients with Gastric Cancer

22 Epigenetic Identification of Paired Box Gene 5 As a Functional Tumor Suppressor Associated with Poor Prognosis in Patients with Gastric Cancer

Promoter Hypermethylation And Downregulation Of Trefoil Factor 2 In Human Gastric Cancer

High Expression Of Tumor Necrosis Factor Receptor-Associated Factor 2 Promotes Tumor Metastasis And Is Associated With Unfavorable Prognosis In Gastric Cancer

E2F1 Maintains Gastric Cancer Stemness Properties by Regulating Stemness-Associated Genes

High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer